Prolong: Putting the PEG in biogenerics

Prolong: Putting the PEG in biogenerics

Prolong Pharmaceuticals Inc. believes that a quick way to develop biogenerics is to pegylate marketed proteins coming off patent to improve their half-life in serum and reduce their immunogenicity and side effects. To that end, Prolong last week licensed OptiPEG pegylation technology from PolyMasc Pharmaceuticals plc. The company believes that OptiPEG is the pegylation technology least mired in patent disputes. ...